


CLAIMS

1. A pharmaceutical composition comprising a therapeutically effective amount of a composition comprising:

a. [2R, 4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-

5 2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;


b. a compound of the Formula I



Formula I

10

or, the open chain Formula IA



Formula IA

wherein R¹ is hydrogen or hydroxy or the pharmaceutically acceptable salts

thereof; and

c. a pharmaceutically acceptable carrier, vehicle or diluent.

2. A pharmaceutical composition as recited in claim 1 wherein R¹ is hydrogen or a pharmaceutically acceptable salt thereof.


3. A pharmaceutical composition as recited in claim 2 comprising the hemicalcium salt of atorvastatin.

4. A pharmaceutical composition as recited in claim 1 wherein R¹ is 2-hydroxy or a pharmaceutically acceptable salt thereof.

5. A method for treating a mammal in need of therapeutic treatment comprising administering to said mammal a therapeutically effective amount of:


a a first compound, said first compound being [2R, 4S]-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; and

b. a second compound, said second compound being a compound having the Formula I



Formula I

or, the open chain Formula IA



Formula IA

wherein R¹ is hydrogen or hydroxy or the pharmaceutically acceptable salts thereof; and

wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable carrier, vehicle or diluent.

6. A method of treating a mammal as recited in claim 5 wherein R¹ is hydrogen or a pharmaceutically acceptable salt thereof.

7. A method of treating a mammal as recited in claim 6 comprising the hemicalcium salt of atorvastatin.

8. A method of treating a mammal as recited in claim 5 wherein R¹ is 2-hydroxy or a pharmaceutically acceptable salt thereof.

9. A method of treating a mammal as recited in claim 5 wherein atherosclerosis is prevented or treated.

10. A method of treating a mammal as recited in claim 5 wherein the progression of atherosclerotic plaques is slowed.

11. A method of treating a mammal as recited in claim 10 wherein the treatment of atherosclerosis causes the regression of atherosclerotic plaques.

12. A method of treating a mammal as recited in claim 5 wherein the therapeutic treatment comprises HDL elevation treatment and antihyperlipidemic treatment.


13. A method of treating a mammal as recited in claim 5 wherein angina is prevented.

14. A method of treating a mammal as recited in claim 5 wherein the therapeutic treatment comprises cardiac risk management.

15. A kit for achieving a therapeutic effect in a mammal comprising a therapeutically effective amount of a composition comprising:


a. [2R, 4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form;

b. a compound having the Formula I



Formula I


or, the open chain Formula IA



Formula IA


wherein R¹ is hydrogen or hydroxy or the pharmaceutically acceptable salts thereof
and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and

- 5 c. means for containing said first and second dosage forms.
16. A kit as recited in claim 15 wherein R¹ is hydrogen or a pharmaceutically acceptable salt thereof.
17. A kit as recited in claim 16 comprising the hemicalcium salt of atorvastatin.
18. A kit as recited in claim 15 wherein R¹ is 2-hydroxy or a pharmaceutically acceptable salt thereof.
- 10 19. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving a therapeutic effect in a mammal, which effect is greater than the individual therapeutic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical
- 15 compositions comprises an amount of a Formula I or IA compound or a pharmaceutically acceptable salt thereof having the Formula I




Formula I

or, the open chain Formula IA




Formula IA

- 5 wherein R¹ is hydrogen or hydroxy and a pharmaceutically acceptable carrier, vehicle or diluent, said first pharmaceutical composition comprising of [2R, 4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester and a pharmaceutically acceptable carrier, vehicle or diluent.
- 10 20. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving a therapeutic effect in a mammal, which effect is greater than the individual therapeutic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of [2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-
- 15 carboxylic acid ethyl ester and a pharmaceutically acceptable carrier, vehicle or diluent, said first pharmaceutical composition comprising an amount of a compound having the Formula I



Formula I

or, the open chain Formula IA



Formula IA

wherein R¹ is hydrogen or hydroxy or the pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier, vehicle or diluent.

[illegible]